TABLE 2.

The treatment for different osteolytic diseases by targeting Osx.

Drug and trials	Disease or cells	Mechanisms	References
Estrogen (ER)	Osteoporosis	By elevating the expressions of Runx2 and Osx	Han et al., 2020
Parathyroid hormone (PTH)	Dental pulp stem cells	By activating Erk and p38 signaling pathways and elevating Osx expression	Ge et al., 2020
Pseudoshikonin I	C2C12 cells	By stimulating Osx and Runx2 via the Akt and Pka signaling pathways	Choi et al., 2018
Gushukang (GSK)	Osteoporosis	By enhancing BMP2/Smads signaling pathway and elevating Osx expression	Chai et al., 2019
Strength training and Raloxifene	Osteopenia	By stimulating/reducing the genesis and activity of osteoblasts/osteoclasts	Stringhetta-Garcia et al., 2016
Turnip bioactive lipids	Osteoporosis	By activating Osx and suppressing Cathepsin K and TNF-α signaling	El-Makawy et al., 2020
Remifentanil	C2C12 cells	By upregulating Osx and Runx2 expression.	Yoon et al., 2019
Low intensity pulsed ultrasound(LIPUS)	Periosteum-derived cells	By upregulating Osx expression through activation of the BMP/Smad canonical pathway	Maung et al., 2020
Bortezomib	Multiple myeloma	By increasing Osx expression and synthesizing the final differentiation markers in osteogenesis	De Matteo et al., 2010
Lenalidomide	Multiple myeloma	By inhibiting the secretion of osteoclastogenic factors exerting on osteogenic cells negatively and no effect on Runx2 and Osx transcription	De Matteo et al., 2010